$SNPX News
Last published 1y ago
- 1y agoTAOXSNPXTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayPR NewswireTAO Synergies Inc. (Nasdaq: TAOX) (the "Company"), formerly Synaptogenix, Inc. (Nasdaq: SNPX), announces that its common stock, listed on the Nasdaq...
- 1y agoSNPXSynaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyPR NewswireTAO Synergies Inc. (the "Company"), formerly Synaptogenix, Inc. (NASDAQ: SNPX), today announced that it will begin trading on Nasdaq under the new...
- 1y agoSNPXSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingPR NewswireSynaptogenix (NASDAQ: SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy...
- 1y agoSNPXSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy...
- 1y agoSNPXSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix Announces $5.0 Million FinancingPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 2y agoSNPXSynaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 3y agoSNPXSynaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyPR NewswireSynaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
- 3y agoSNPXSynaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseasePR NewswireBryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK, Sept. 26, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX)
- 3y agoSNPXBryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyPR NewswirePositive changes in ALS gene expression and increased cellular viability met with statistical significance of p<.001 NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or
- 3y agoSNPXSynaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisPR NewswireStudy will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients NEW YORK, July 19, 2023 /PRNewswire/ -- Synaptogenix, Inc.
- 3y agoSNPXSynaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeurosciencePR NewswirePhase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint data selected by independent committee for presentation NEW YORK, July 13, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX)
- 3y agoOBLGPMCBPTPISNPX+1Oblong Appoints Two New Directors to its BoardBusiness WireJonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new
- 3y agoSNPXSynaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesPR NewswireAnnounces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patientsMaintains strong financial position with approximately $37.5 million
- 3y agoSNPXSynaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's DiseasePR NewswireNEW YORK, Dec. 16, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative
- 3y agoSNPXSynaptogenix Announces $15 Million Private Placement with Existing InvestorsPR NewswireTopline data from NIH-supported Phase 2 clinical trial for advanced AD patients expected during the current quarter NEW YORK, Nov. 18, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the
- 4y agoSNPXSynaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022PR NewswireSynaptogenix is one of few companies developing therapeutics for advanced Alzheimer's disease (AD); no such drug has received FDA approval to date Topline data from NIH-supported Phase 2 clinical trial for advanced
- 4y agoSNPXSynaptogenix Welcomes Lecanemab Phase 3 Trial ResultsPR NewswireSynaptogenix expecting data from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter 2022 NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging
- 4y agoSNPXSynaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News NetworkPR NewswireNEW YORK, Aug. 12, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that Dr. Daniel L. Alkon , the Comp
- 4y agoSNPXSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 DataPR NewswireConference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK, July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative
- 4y agoSNPXSynaptogenix Announces Corporate Update Conference CallPR NewswireNEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate updat
- 4y agoSNPXSynaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial DataPR NewswireDose optimization prepares the Company for its next phase of Bryostatin clinical development Company expects to announce topline data from its NIH sponsored Phase 2 clinical study during the fourth quarter of 2022 NEW YORK, July 20, 2022 /PRNewswire/
- 4y agoSNPXSynaptogenix to Present at the Cell SymposiumPR NewswireNEW YORK, May 17, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon
- 4y agoSNPXSynaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease TrialPR Newswire- Top line results expected during the fourth quarter of 2022 - Data Safety Monitoring Board has confirmed no adverse safety issues NEW YORK, April 19, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmac
- 4y agoSNPXNew Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's DiseasePR NewswireTreatment with Bryostatin shown to increase blood vessel health, a key factor for prevention and disease reversal National Institutes of Health (NIH)-sponsored Phase 2b clinical trial of Bryostatin-1 in Alzheimer's disease (AD) patients currently under
- 4y agoSNPXSynaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development SummitPR NewswireNEW YORK, March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alk
- 4y agoSNPXSynaptogenix to Present at Sachs 5th Annual Neuroscience Innovation ForumPR NewswireNEW YORK, March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alko
- 4y agoSNPXSynaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)PR NewswireNEW YORK, March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chie
- 4y agoSNPXSynaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple SclerosisPR NewswireNEW YORK, Feb. 23, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop Bryostatin-1 for the treatment of
- 4y agoSNPXSynaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease PatientsPR NewswireNEW YORK, Feb. 1, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that its peer-reviewed scientific ma
- 5y agoSNPXSynaptogenix Announces Participation at the Benzinga Healthcare Small Cap ConferencePR NewswireNEW YORK, Sept. 28, 2021 /PRNewswire/ -- Synaptogenix, Inc (NASDAQ:SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it will be participating at the Benzinga Healthcare Sma
- 5y agoSNPXSynaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment ConferencePR NewswireNEW YORK, Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (NASDAQ:SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it will be featured as a presenting company at the H.C.
- 5y agoSNPXSynaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X SyndromePR NewswireNEW YORK, Aug. 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it signed a memorandum of understanding ("MOU") wi
- 5y agoSNPXSynaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021PR NewswireNEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Assoc
- 5y agoSNPXSynaptogenix Announces Conference Call to Discuss AAIC Abstract FindingsPR NewswireNEW YORK, July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will hold a conference call for investors to discuss
- 5y agoSNPXSynaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above BaselinePR NewswireNEW YORK, July 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract has been accepted at the Alzheimer's Associ
- 5y agoSNPXSynaptogenix Announces Regenerative Patent Award to Treat Alzheimer's DiseasePR NewswireNEW YORK, July 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that a new patent has been awarded by the U.S. Patent and Tra
- 5y agoSNPXSynaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News NetworkPR NewswireNEW YORK, June 24, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Daniel Alkon, the Company's President and Chief Sci
- 5y agoSNPXSynaptogenix Announces $12.5 Million Private PlacementPR NewswireNEW YORK, June 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it has executed securities purchase agreements to raise
- 5y agoSNPXSynaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial UpdatePR NewswireNEW YORK, June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health ("NIH"
- 5y agoSNPXSynaptogenix Responds to FDA Approval of AducanumabPR NewswireNEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement following the announced FDA approval of Biogen's new
- 5y agoSNPXSynaptogenix Announces Approval for Nasdaq Stock Market ListingPR NewswireNEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced today that it has been approved to uplist to The Nasdaq Capital Market
- 5y agoSNPXSynaptogenix Announces Plan to Uplist on the Nasdaq Stock MarketPR NewswireNEW YORK, May 19, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced that the Company's Board of Directors has approved a one-for-four reve